GIP and obesity due to melanocortin 4 receptor deficiency: Tirzepatide, a once weekly dual agonist of GIP and GLP-1 receptors, is used for the treatment of both obesity and type 2 diabetes, leading to significant weight loss that is greater than seen with GLP-1 analogs alone (18).